1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

 
• By Emily Hayes

Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.

Clinical trials
NEW NSCLC DATA FOR KEYTRUDA

Merck & Co. Inc.'s PD-1 inhibitor Keytruda's(pembrolizumab) position in first-line non-small cell lung cancer (NSCLC) is now even stronger with the KEYNOTE-042 study showing the drug works well as monotherapy across levels of PD-L1 expression.

NSCLC is expected to account for close to half of the total immuno-oncology (IO) market and Keytruda has been consistently...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Immuno-oncology

More from Anticancer